316
Participants
Start Date
May 6, 2016
Primary Completion Date
July 1, 2025
Study Completion Date
July 1, 2025
Lurbinectedin
lurbinectedin (PM01183) 4 mg vials
Irinotecan
irinotecan 40 mg, 100 mg or 300 mg vials
IRCCS Fondazione Candiolo (Turin), Torino
Helios Klinikum Berlin Buch, Berlin
Helios Kilinikum Bad Saarow, Bad Saarow
Hospital Clínico Universitario de Santiago, Santiago de Compostela
Hospital Universitario Puerta de Hierro, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Madrid Sanchinarro, Madrid
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Virgen Del Rocio, Seville
Hospital Universitario Miguel Servet, Zaragoza
Centre Léon Bérard, Lyon
The University of Texas MD Anderson Cancer Center, Houston
Sarcoma Oncology Center, Santa Monica
Institut Gustave Roussy, Villejuif
Massachusetts General Hospital -, Boston
Beth Israel Deaconess Medical Center, Boston
Campus Biomedico, Roma
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Univeristari Vall d'Hebron, Barcelona
Inselspital Bern - Medizinische Onkologie, Bern
Lead Sponsor
PharmaMar
INDUSTRY